The United States Food and Drug Administration (FDA) has leveled serious regulatory charges against Beijing-based BMC Medical Co Ltd, the manufacturer behind the Luna series of positive airway pressure devices. In a formal warning letter issued on May 20, 2026, federal regulators cited the company for distributing “adulterated and misbranded” medical devices, alleging that significant design and software modifications were implemented without the necessary premarket authorization.
The regulatory action stems from a comprehensive inspection of a facility in Dublin, Ohio, operated by React Health Inc (formerly 3B Medical), which serves as the primary importer and distributor for BMC Medical’s equipment in the United States. The FDA’s findings suggest a pattern of unauthorized engineering changes and a failure to disclose critical firmware corrections intended to resolve life-impacting device failures.
Chronology of Regulatory Findings
The seeds of the current dispute were sown during a rigorous FDA inspection conducted in December 2025. Federal investigators scrutinized the regulatory compliance of devices imported by React Health, identifying BMC Medical as the specification developer and the holder of the 510(k) clearance for the affected product lines.
Following months of analysis, the FDA’s May 20, 2026, letter solidified the government’s stance. The timeline of the alleged violations includes:
- 2016: The original Luna CPAP and Auto CPAP systems receive 510(k) clearance from the FDA, establishing the baseline for safe and effective operation.
- December 2025: FDA inspectors visit the React Health facility in Dublin, Ohio, to evaluate quality systems and regulatory filings.
- Early 2026: Evidence emerges regarding the distribution of the "G3X APAP" model, which the FDA maintains is a distinct, unapproved iteration of the previously cleared 2016 technology.
- May 19, 2026: The cutoff date for the FDA’s review; regulators confirm that no report was ever filed regarding a critical firmware correction for an unexpected shutdown issue.
- May 20, 2026: The FDA formally issues the warning letter, demanding immediate corrective action and a written response within 15 business days.
Technical Analysis: The Scope of Unauthorized Modifications
The core of the FDA’s concern centers on the G3X APAP model. According to the agency, BMC Medical bypassed the required 510(k) premarket notification process by introducing significant changes to a device that was fundamentally different from its original cleared version.
Algorithmic and Firmware Overhauls
The FDA identified that BMC Medical introduced new recognition features into the G3X’s firmware, specifically designed to distinguish between central and obstructive hypopnea events. These features—which include monitoring for flow limitation, respiratory effort-related arousals, and periodic breathing—are not merely aesthetic updates. The agency argues that these algorithmic changes directly impact the device’s diagnostic capabilities. Because these modifications dictate how the machine responds to a patient’s breathing patterns, they fundamentally alter the “accuracy of event classification” and the reliability of data provided to clinicians for patient care.
Hardware and Biocompatibility Concerns
Beyond the software, the physical hardware of the devices underwent material changes. The FDA highlighted modifications to the sound abatement system—a critical component of the gas pathway. By altering the materials used in the airflow path, BMC Medical introduced potential biocompatibility risks that had not been vetted through the FDA’s rigorous safety testing protocols. Furthermore, the installation of a new chip on the printed circuit board assembly, necessitated by the updated software, constitutes a significant design change that the agency maintains could compromise the device’s safety and efficacy.
Failure to Report: The "Shutdown" Incident
One of the most concerning aspects of the FDA’s warning letter is the allegation that BMC Medical failed to report a known safety issue. Many users of the Luna G3 APAP series—specifically those operating on firmware version G3-2.00.76—reported that the devices would suffer from unexpected shutdowns during sleep.
For patients with obstructive sleep apnea, the CPAP device is a life-sustaining tool. A sudden, unexplained loss of therapy can lead to immediate respiratory distress and long-term health complications. While BMC Medical acknowledged the fault internally by releasing a firmware update (version G3-2.00.77) to resolve the shutdown issue, they failed to fulfill their legal obligation to report this “medical device correction” to the FDA within the mandated 10-working-day window.
By keeping this correction quiet, the company deprived both regulators and the medical community of transparency regarding the reliability of the hardware being used by thousands of American patients.
Implications for Patients and Clinicians
The FDA’s warning creates a complicated landscape for both the patients currently relying on these devices and the clinicians who prescribe them.
For Patients
The primary risk for patients is the lack of clinical validation for the G3X model. When a medical device is modified without FDA oversight, there is no guarantee that the device will perform as expected. Patients using the G3X or devices with outdated firmware may be receiving inaccurate therapeutic pressure or, in the case of the shutdown bug, no therapy at all. The FDA’s request for BMC Medical to cease activities related to these devices could potentially lead to inventory freezes, creating uncertainty regarding the availability of replacement parts or units.
For Clinicians
Physicians who rely on data generated by the Luna series to manage patient therapy are now in a difficult position. Because the FDA has flagged the software algorithms as unvetted, the data provided by these devices—such as Apnea-Hypopnea Index (AHI) scores and flow limitation metrics—must be treated with skepticism. Clinicians may need to re-evaluate treatment plans for patients currently using these specific models to ensure that therapy is not being adjusted based on potentially flawed diagnostic data.
Official Responses and Regulatory Outlook
As of the date of publication, neither React Health nor BMC Medical has provided a formal statement or responded to inquiries regarding the FDA’s findings.
The FDA’s directive is clear: BMC Medical must cease any activities that contribute to the misbranding or adulteration of their devices. The company has been given a 15-business-day window to respond in writing, detailing exactly how they intend to rectify these violations. This response must include a comprehensive plan to address the unapproved modifications and a strategy for ensuring all future medical device corrections are reported in accordance with federal law.
Failure to comply with the FDA’s demands could lead to more severe enforcement actions, including seizure of products, injunctions against the company, or the permanent revocation of their ability to import devices into the United States.
Conclusion: A Call for Accountability
The case of BMC Medical serves as a cautionary tale regarding the critical nature of the 510(k) process. In the medical device industry, engineering "improvements" cannot be made in a vacuum. Every change to firmware, material composition, or internal logic must be weighed against the potential impact on patient safety. By attempting to expedite the evolution of the Luna line without proper regulatory filing, BMC Medical has not only risked federal penalties but has also undermined the trust that patients and providers place in their therapeutic equipment.
As the industry waits for a response from the manufacturer, the regulatory spotlight remains fixed on the importance of transparency in the medical supply chain. For now, patients are encouraged to monitor their devices for any signs of unexpected behavior and consult with their sleep medicine specialists regarding the continued use of their specific Luna device models.
